» Articles » PMID: 34360973

Novel Therapeutic Approaches for Alzheimer's Disease: An Updated Review

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2021 Aug 7
PMID 34360973
Citations 63
Authors
Affiliations
Soon will be listed here.
Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disease and accounts for most cases of dementia. The prevalence of AD has increased in the current rapidly aging society and contributes to a heavy burden on families and society. Despite the profound impact of AD, current treatments are unable to achieve satisfactory therapeutic effects or stop the progression of the disease. Finding novel treatments for AD has become urgent. In this paper, we reviewed novel therapeutic approaches in five categories: anti-amyloid therapy, anti-tau therapy, anti-neuroinflammatory therapy, neuroprotective agents including N-methyl-D-aspartate (NMDA) receptor modulators, and brain stimulation. The trend of therapeutic development is shifting from a single pathological target to a more complex mechanism, such as the neuroinflammatory and neurodegenerative processes. While drug repositioning may accelerate pharmacological development, non-pharmacological interventions, especially repetitive transcranial magnetic stimulation (rTMS) and transcranial direct current stimulation (tDCS), also have the potential for clinical application. In the future, it is possible for physicians to choose appropriate interventions individually on the basis of precision medicine.

Citing Articles

Clinical Importance of Amyloid Beta Implication in the Detection and Treatment of Alzheimer's Disease.

Pokrzyk J, Kulczynska-Przybik A, Guzik-Makaruk E, Winkel I, Mroczko B Int J Mol Sci. 2025; 26(5).

PMID: 40076562 PMC: 11900921. DOI: 10.3390/ijms26051935.


The role of protein phosphorylation modifications mediated by iron metabolism regulatory networks in the pathogenesis of Alzheimer's disease.

Liu F, Yang S, Shi K, Li D, Song J, Sun L Front Aging Neurosci. 2025; 17:1540019.

PMID: 40071123 PMC: 11893871. DOI: 10.3389/fnagi.2025.1540019.


Ellagic Acid: A Green Multi-Target Weapon That Reduces Oxidative Stress and Inflammation to Prevent and Improve the Condition of Alzheimer's Disease.

Alfei S, Zuccari G Int J Mol Sci. 2025; 26(2).

PMID: 39859559 PMC: 11766176. DOI: 10.3390/ijms26020844.


Relationship between enriched environment and neurodegeneration: a review from mechanism to therapy.

Xu Y, Chen Y, Xing J, Yao J Clin Epigenetics. 2025; 17(1):13.

PMID: 39849536 PMC: 11761206. DOI: 10.1186/s13148-025-01820-4.


CEST imaging combined with H-MRS reveal the neuroprotective effects of riluzole by improving neurotransmitter imbalances in Alzheimer's disease mice.

Shen Y, Zhang X, Liu S, Xin L, Xuan W, Zhuang C Alzheimers Res Ther. 2025; 17(1):20.

PMID: 39806490 PMC: 11726951. DOI: 10.1186/s13195-025-01672-3.


References
1.
Friedman E, Shih R, Langa K, Hurd M . US Prevalence And Predictors Of Informal Caregiving For Dementia. Health Aff (Millwood). 2015; 34(10):1637-41. PMC: 4872631. DOI: 10.1377/hlthaff.2015.0510. View

2.
Wang X, Sun G, Feng T, Zhang J, Huang X, Wang T . Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer's disease progression. Cell Res. 2019; 29(10):787-803. PMC: 6796854. DOI: 10.1038/s41422-019-0216-x. View

3.
Salameh T, Rhea E, Talbot K, Banks W . Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimer's and Parkinson's disease therapeutics. Biochem Pharmacol. 2020; 180:114187. PMC: 7606641. DOI: 10.1016/j.bcp.2020.114187. View

4.
Ben Haim L, Ceyzeriat K, Carrillo-de Sauvage M, Aubry F, Auregan G, Guillermier M . The JAK/STAT3 pathway is a common inducer of astrocyte reactivity in Alzheimer's and Huntington's diseases. J Neurosci. 2015; 35(6):2817-29. PMC: 6605603. DOI: 10.1523/JNEUROSCI.3516-14.2015. View

5.
Baldermann J, Hardenacke K, Hu X, Koster P, Horn A, Freund H . Neuroanatomical Characteristics Associated With Response to Deep Brain Stimulation of the Nucleus Basalis of Meynert for Alzheimer's Disease. Neuromodulation. 2017; 21(2):184-190. DOI: 10.1111/ner.12626. View